TO SORAFENIB
Disclaimer: These predictions are for research purposes only. They do not constitute medical advice and require clinical validation.
Overview
| Property | Value |
|---|---|
| Drug Name | TO SORAFENIB |
| DrugBank ID | DB00398 |
| HSA Status | Registered with Health Sciences Authority |
| KG Predictions | 66 |
| DL Predictions (≥0.7) | 50 |
Predicted Indications
The following indications are predicted based on TxGNN knowledge graph analysis:
| Indication | Source | Evidence |
|---|---|---|
| liver cancer | TxGNN Knowledge Graph | L5 |
| hepatocellular carcinoma | TxGNN Knowledge Graph | L5 |
| undifferentiated carcinoma of liver and intrahepatic biliary tract | TxGNN Knowledge Graph | L5 |
| pediatric hepatocellular carcinoma | TxGNN Knowledge Graph | L5 |
| squamous cell carcinoma of liver and intrahepatic biliary tract | TxGNN Knowledge Graph | L5 |
| metastasis from malignant tumor of colon | TxGNN Knowledge Graph | L5 |
| gastrointestinal stromal tumor | TxGNN Knowledge Graph | L5 |
| fibrolamellar hepatocellular carcinoma | TxGNN Knowledge Graph | L5 |
| adenocarcinoma of liver and intrahepatic biliary tract | TxGNN Knowledge Graph | L5 |
| clear cell renal carcinoma | TxGNN Knowledge Graph | L5 |
Evidence Summary
External Resources
Generated by SgTxGNN on 2026-03-11